
(IN BRIEF) BioNTech and OncoC4 have entered into an exclusive license and collaboration agreement to develop and commercialize OncoC4’s anti-CTLA-4 monoclonal antibody candidate, ONC-392. The candidate aims to delete immunosuppressive T cells in the tumor microenvironment but spare T cells … Read the full press release